Acura Pharmaceuticals (ACUR) 1.22 $ACUR
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma
PR Newswire - Thu May 08, 7:09AM CDT
On Wednesday, May 7, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. During the session, eight out of ten sectors ended on a positive note. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, with the index advancing 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) and Acura Pharmaceuticals Inc (NASDAQ: ACUR). Free technical research on FRX, VRX, IPCI and ACUR can be downloaded upon signing up at:
Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
Marketwire - Thu May 08, 5:31AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Ranbaxy Inc. to dismiss, without prejudice, its patent infringement action pending against Ranbaxy in the United States District Court for the District of Delaware. In the suit, Acura alleges that a generic of Acura's AVERSION(R) oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA(R), for which Ranbaxy is seeking approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) infringes U.S. patents owned by Acura.
Acura Pharmaceuticals Announces First Quarter 2014 Financial Results
Marketwire - Wed May 07, 4:55AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2014.
Acura Pharmaceuticals posts lower net loss of USD4.1m in Q1 2014
M2 - Tue May 06, 6:08AM CDT
Specialist pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) on Monday declared a net loss of USD4.1m (USD0.08 per diluted share) for the first quarter ended 31 March 2014.
Acura Pharmaceuticals to Host First Quarter 2014 Financial Results Conference Call on May 6, 2014
Marketwire - Mon Apr 28, 2:41PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2014 following the close of financial markets on Monday, May 5, 2014. The Company will host a conference call to discuss the results on Tuesday, May 6, 2014 at 8:30 a.m. ET.
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer
M2 - Thu Apr 10, 5:46AM CDT
Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) disclosed on Thursday the termination of the license of its AVERSION Technology to Pfizer.
Acura Pharmaceuticals Announces Return of Product Rights
Marketwire - Thu Apr 10, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION(R) Technology and the return to Acura of the FDA approved Oxecta(R) (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. The AVERSION(R) Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Faruqi & Faruqi, LLP Launches An Investigation Against Acura Pharmaceuticals, Inc. (ACUR) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Thu Mar 20, 1:56PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company"
(NasdaqCM: ACUR) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for the 2014 Restricted Stock Unit Award Plan ("Plan" .
Acura Pharmaceuticals, Inc. (ACUR) in Focus: Stock Moves 7.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:44AM CDT
Acura Pharmaceuticals, Inc. (ACUR) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.
Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.
Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.
Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.
Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
Pharma Stocks Technical Briefing -- Research on Forest Laboratories, Valeant Pharma, IntelliPharmaCeutics Intl., and Acura Pharma
PR Newswire - Thu May 08, 7:09AM CDT
On Wednesday, May 7, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. During the session, eight out of ten sectors ended on a positive note. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, with the index advancing 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), Valeant Pharmaceuticals International Inc. (NYSE: VRX), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) and Acura Pharmaceuticals Inc (NASDAQ: ACUR). Free technical research on FRX, VRX, IPCI and ACUR can be downloaded upon signing up at:
Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
Marketwire - Thu May 08, 5:31AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Ranbaxy Inc. to dismiss, without prejudice, its patent infringement action pending against Ranbaxy in the United States District Court for the District of Delaware. In the suit, Acura alleges that a generic of Acura's AVERSION(R) oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA(R), for which Ranbaxy is seeking approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) infringes U.S. patents owned by Acura.
Acura Pharmaceuticals Announces First Quarter 2014 Financial Results
Marketwire - Wed May 07, 4:55AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2014.
Acura Pharmaceuticals posts lower net loss of USD4.1m in Q1 2014
M2 - Tue May 06, 6:08AM CDT
Specialist pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) on Monday declared a net loss of USD4.1m (USD0.08 per diluted share) for the first quarter ended 31 March 2014.
Acura Pharmaceuticals to Host First Quarter 2014 Financial Results Conference Call on May 6, 2014
Marketwire - Mon Apr 28, 2:41PM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the first quarter 2014 following the close of financial markets on Monday, May 5, 2014. The Company will host a conference call to discuss the results on Tuesday, May 6, 2014 at 8:30 a.m. ET.
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer
M2 - Thu Apr 10, 5:46AM CDT
Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) disclosed on Thursday the termination of the license of its AVERSION Technology to Pfizer.
Acura Pharmaceuticals Announces Return of Product Rights
Marketwire - Thu Apr 10, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION(R) Technology and the return to Acura of the FDA approved Oxecta(R) (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. The AVERSION(R) Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Faruqi & Faruqi, LLP Launches An Investigation Against Acura Pharmaceuticals, Inc. (ACUR) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Thu Mar 20, 1:56PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company"
(NasdaqCM: ACUR) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for the 2014 Restricted Stock Unit Award Plan ("Plan" . Acura Pharmaceuticals, Inc. (ACUR) in Focus: Stock Moves 7.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:44AM CDT
Acura Pharmaceuticals, Inc. (ACUR) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.
Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.
Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.
Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.
Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
